Please use this identifier to cite or link to this item:
Title: Relationship of JAK2 (V617F) allelic burden with clinico-haematological manifestations of philadelphia-negative myeloproliferative neoplasms
Authors: Yow, K.S.
Liu, X.
Chai, C.N.
Tung, M.L. 
Yan, B.
Christopher, D.
Ong, K.H.
Ooi, M.G. 
Keywords: Allelic burden
Myeloproliferative disease
Issue Date: 2020
Publisher: Asian Pacific Organization for Cancer Prevention
Citation: Yow, K.S., Liu, X., Chai, C.N., Tung, M.L., Yan, B., Christopher, D., Ong, K.H., Ooi, M.G. (2020). Relationship of JAK2 (V617F) allelic burden with clinico-haematological manifestations of philadelphia-negative myeloproliferative neoplasms. Asian Pacific Journal of Cancer Prevention 21 (9) : 2805-2810. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: JAK2 (V617F) allelic burden is the main genetic driver behind and a potential differentiator between individual myeloproliferative neoplasm (MPN) subtypes. This study aimed to explore the relationship between JAK2 (V617F) allelic burden, MPN subtypes and their clinico-haematological manifestations in a Singapore-based cohort. Analysis was performed on a retrospectively collected dataset of 128 patients diagnosed with JAK2 (V617F) positive Philadelphianegative MPNs between 2016 to 2017 in Singapore. Genomic analysis was conducted on blood samples via DNA extraction and Droplet Digital Polymerase Chain Reaction (ddPCR). The mean age was 62.4 (SD=14.1). 85 out of the 128 (66.4%) patients were male. There was a statistically significant difference in allelic burdens between the different MPN disease subtypes ?2(3) = 9.064, p=0.028, with essential thrombocytosis (ET) patients having the lowest mean JAK2 percentage allelic burden (26.5%). Patients with an allelic burden >50% had higher leukocyte counts (MWU 1016.5, p=0.001), haemoglobin levels (MWU 1287.0, p=0.045), lactate dehydrogenase levels (MWU 611.5, p=0.001), and lower platelet levels (MWU 1164.0, p=0.008). Subgroup analysis revealed none of these correlations was significant in the ET subgroup. The results are largely in concordance with previous research in Asian cohorts demonstrating the association between allelic burden and clinico-haematological manifestations of MPN. However, in the ET subgroup, the JAK2 (V617F) allelic burden do not correlate positively for haematological parameters which is only seen in Asian patients. © 2020 Asian Pacific Organization for Cancer Prevention.
Source Title: Asian Pacific Journal of Cancer Prevention
ISSN: 15137368
DOI: 10.31557/APJCP.2020.21.9.2805
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_31557_APJCP_2020_21_9_2805.pdf296.4 kBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons